On the stock market since 2018, it operates in the world of heavy industry. It has 6,250 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.3B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 9% a year on average.
Over the last 12 months, company executives reported 29 buys and 15 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.20 per share each year — regular cash for whoever holds the stock.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 48/100.
On our five-subject report card, ACA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ACA is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.